This generation forms the basis of currently FDA-approved CAR-T therapies, exemplified by “KTE-C19” (axicabtagene ciloleucel) targeting CD19 (approved under the brand name Yescarta for treating certain types of lymphomas) (95). The gene discussed is CD19; the disease is lymphoma.